Key opinion leaders review the use of antibody-drug conjugates (ADCs) in treating HR+/HER2- metastatic breast cancer, and how they counsel patients before starting them on therapy with an ADC.
Virginia Kaklamani, MD
Advertisement
Articles by Virginia Kaklamani, MD
Experts discuss the complexity of defining endocrine resistance in patients with HR+/HER2- metastatic breast cancer and the options for treatment.
Virginia Kaklamani, MD, presents the case of a 47-year-old premenopausal woman diagnosed with HR+/HER2- metastatic breast cancer for discussion.
Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, offer an overview of HR+/HER2- metastatic breast cancer and detail the standard-of-care first-line therapy options.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5